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Introduction
The aim of this article is to examine the types of ethical 
issue that arise with clinical research in lung cancer and to 
suggest possible resolutions. Lung cancer research does 
not raise any unique challenges. Those discussed here 
have arisen in other types of research. However, as the 
brief history below shows, ethical problems have hindered 
research in this area because it has features, such as high 
mortality, that raises such challenges particularly sharply, for 
example, randomisation and equipoise remain problematic. 
It is on these acute ethical issues that this article will 
primarily focus. 
A brief history of lung cancer research
Lung cancer is one of a group of conditions said to carry 
a stigma related to the idea that sufferers have in general 
contributed to it (by smoking) (1). This has been said to 
lie behind its status as under-researched (2). However, 
Timmerman’s historical research shows this phenomenon 
to be fairly recent (3). In the 1950–1960s no such stigma 
was attached to the condition. The UK Medical Research 
Council (MRC) viewed it as a particularly promising area of 
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research as it was a relatively well-understood condition. It 
was thus the subject of much research activity. At the same 
time, the randomised controlled trial (RCT) had come to be 
seen as the gold standard design for evaluation in evidence 
based health care and, as such, was the chosen vehicle for 
MRC research. Two problems followed for lung cancer 
research, one ethical and one empirical. The ethical one was 
that in order to run an RCT there needs to be at least two 
credible treatment options to compare. Often clinicians did 
not feel this to be the case, to use the term we shall soon 
introduce more fully, they lacked equipoise. In particular, 
clinicians felt there was insufficient evidence to run trials 
comparing novel chemotherapy with the standard surgical 
treatments (3). Randomised trials could thus be run only in 
the investigation of fringe cases or in comparing treatments 
with marginal variation rather than in the investigation of 
the major questions of lung cancer treatment. The empirical 
problem was that the results of such trials were disappointing. 
And at the same time, the link between smoking and lung 
cancer became established both empirically and in the minds 
of clinicians and the public. It seemed that the most effective 
treatment for lung cancer was via the prevention of smoking. 
Lung cancer developed a reputation of being difficult to study 
as well as associated with what was becoming a stigmatised 
activity, smoking, in turn, what has been termed a culture of 
nihilism developed (4,5).
Arguably, the situation has gradually changed. In the first 
place, public health policy on smoking may have hit bedrock, 
a large minority of people are resistant despite bans on 
smoking in public places, high rates of tax and garish public 
information. The rates are changing unevenly also, with 
women and lower economic groups faring worse (6). Lung 
cancer remains the leading cause of cancer deaths worldwide 
and its early detection and treatment must now be considered 
a public health priority (2). There are also new developments 
in treatments which require an evidence base (7) and, as this 
paper will show, developments in research design that help 
researchers to tackle some of the ethical problems with which 
the earlier MRC trials struggled. The paper now turns to 
the specific ethical challenges in lung cancer research. This 
is done in research process order, beginning with trial design 
and ending with dissemination.
Trial design
As in the 1950–1960s, randomisation remains the preferred 
method for isolating genuine from spurious effects when 
testing clinical treatments (8) with the RCT entrenched as 
the gold standard design (9). This requires there to be viable 
comparators, it would be both unethical and rather odd to 
test a treatment of known benefit against one of unknown 
benefit. A more difficult ethical question arises, however, 
when there is disagreement of the viability of comparators. 
This question is usually put in terms of equipoise. 
Approximately, equipoise is the condition of there being 
insufficient evidence to prefer one treatment over another, 
paradigmatically novel over standard treatment. Equipoise 
can be thought of as either a subjective or an intersubjective 
phenomenon. As subjective, it is the belief of an individual, 
for example, that a clinician is in equipoise over whether to 
use the novel or standard treatment. The problem with this 
as a basis for setting up and running RCTs is that clinicians 
will often have preferences one way or another, perhaps 
based on their own anecdotes and experience. If this were 
to be used as a requirement for RCTs then it is likely that 
few could ever be run. The preferred notion of equipoise 
is thus generally the intersubjective one, first suggested by 
Freedman and which he termed “clinical equipoise” (10), 
this exists where the clinical community is undecided over 
which of two or more treatments to prefer. This notion did 
not exist in the 1950–1960s, a fact that could lie behind a 
problem of clinicians being reluctant to randomise “their” 
patients to “others’” treatments at that time.
Clinical equipoise does not resolve all ethical issues 
concerning randomisation. At least four might arise in lung 
cancer studies. 
• The first concerns the point at which clinical equipoise 
can be said to exist. It is unlikely that clinicians will be 
split 50/50 in their preference for one treatment over 
another. But would 40/60 still constitute equipoise, or 
20/80? And should weight be given to clinicians with 
more experience? 
• The second problem concerns the issue of who is 
supposed to be in equipoise i.e., whose equipoise 
has priority? In particular, is it reasonable to offer 
randomisation to a patient who is not in equipoise but 
rather has a strong preference for one treatment arm 
over another? We return to this point in the discussion 
of informed consent (in the next section) when we 
consider the problem of desperate volunteers. 
• The third (and related to the second) problem 
concerns the clinician who is a long way from 
equipoise, perhaps in relation to a particular patient. 
One feature of many lung cancer studies is that the 
treatments can vary enormously. Thus an individual 
patient or clinician might view as important not 
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simply the likelihood of certain outcomes of a 
treatment, such as relief of symptoms, but also 
what is involved in the treatment itself. Offered a 
choice between radical surgery, chemotherapy and 
radiotherapy, different individuals might have quite 
different preferences based on previous experiences, 
fears and beliefs. Although the clinical community 
and perhaps the patients themselves might be in 
equipoise about efficacy they may nonetheless not be 
in equipoise about which arm of the study they would 
prefer. For this reason an individual may prefer, and 
an individual clinician prefer to offer, non-randomised 
treatment, outside the trial if necessary. 
• Finally, the range of clinicians involved in a patient’s 
care [i.e., the lung cancer multi-disciplinary team 
(MDT)] will be wider than the immediate study team. 
What should be said of their equipoise (or its lack) in 
relation to particular patients? For example, if they 
are asked their opinion by the patient, or they have a 
small role in the study itself, such as alerting the team 
to potential recruits?
Some help can be offered with regard to these four 
problems. Regarding the first is the growth of systematic 
evidence reviews. These give the researcher access to all 
relevant evidence such that clinical equipoise comes close 
to being a matter of fact rather than opinion. Where a 
systematic review concludes there is insufficient evidence to 
recommend one treatment over another it seems reasonable 
to state there is community equipoise. The second problem 
will be tackled more fully in the discussion of desperate 
volunteers below. However, both the second and third 
problem can be at least partially tackled at the research 
design stage through the fairly recent trend towards patient 
and public involvement (PPI) in research (11). PPI can 
help pick up early any potential problem in the equipoise 
of patients and thus in their recruitment on a randomised 
basis. Where this is the case new and alternative research 
designs offer another aid for the researcher. For example, 
where patient equipoise is a problem alternatives might be 
considered, such as patient preference designs, pragmatic 
designs, cohort multiple RCTs design and outcome adaptive 
allocation trials (12-15) (although there are ethical concerns 
too about unequal allocation and adaptive preference 
designs as well as a general requirement for a larger sample 
size (16,17). Finally, as with PPI, a similar involvement of 
a wider range of clinicians in research development should 
also help alleviate the fourth problem.
In summary, the ethical issues of trial design in lung 
cancer research revolve around the notion of equipoise. 
Equipoise is can be problematic for lung cancer trials 
because the interventions being tested may involve 
substantial and onerous degrees of intervention for the 
participant, for example radical surgery or radiotherapy. 
However, developments such as systematic review, PPI and 
research design can help the researcher to tackle some of 
the problems at the research design stage.
Recruitment
It is all-but universally accepted that participants in health 
care research must give informed consent, although there 
are exceptions, particularly where those without capacity 
to consent are involved (18). A standard model of informed 
consent includes three elements such that it is said to occur 
where a person with capacity freely consents to a study 
having been adequately informed (and having understood 
that information) (19). These three elements to informed 
consent are capacity, information and understanding, 
and voluntariness. In the main, capacity does not greatly 
impinge in lung cancer research as in general it involves 
adults with capacity. In older patients, dementia may be 
an issue but we shall leave that aside here and focus on the 
other two elements, where there are issues of importance in 
lung cancer research. 
Information and understanding
The first issue straddles capacity and understanding: it 
is whether many or perhaps most patients are unable to 
understand complex trials adequately. Mackillop et al. 
compared the decisions of a panel of lay people and of 
doctors when asked to consider hypothetical participation 
to six clinical studies of treatments for non-small cell lung 
cancer (20). The study found, first, that lay persons were 
more likely to consent than doctors and, in particular, that 
they did not discern a difference in acceptability between 
two clinical trials which were markedly different from the 
point of view of the doctors. The researchers suggest that 
“lay people appear ill-equipped to judge for themselves 
the risks and benefits of participation in a clinical trial” 
(P392). The study found also that lay people were more 
affected by framing effects than the panel of doctors (that 
is, the decisions of lay people were more affected by the 
way in which information was presented). Again, this 
leads to doubts about lay people’s ability to make truly 
informed decisions. This type of finding is echoed in a large 
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number of empirical studies of informed consent (21,22). 
Alternatives based on giving participants only partial 
information have been suggested [based on a Zelen design 
in which participants are asked to consent after they have 
been randomised and then given information primarily 
about the arm to which they are randomized (23,24)]. 
However, these have generally been thought unacceptable, 
and empirical studies of participants suggest that they would 
rather give imperfect consent than none at all (25). Doing 
without any consent has only been credibly defended with 
regard to data-based research and research in emergency 
situations (26,27).
A second i s sue ,  re la ted  to  the  f i r s t ,  concerns 
understanding.  This  i s  the so-cal led therapeutic 
misconception first identified in psychiatric research (28) 
but which has been and is still discussed in relation to 
clinical trials generally (29). The misconception occurs 
where those who consent to a clinical trial believe they are 
being treated primarily as patients rather than research 
participants. The misconception is significant, or becomes 
significant, where it is tied up with a misunderstanding of 
important elements of the study, such as risk and benefit (30). 
Where participants say of randomisation, for example, that 
the computer “selected a treatment” for them, this may 
mask a misunderstanding that the choice was somehow 
made in his or her best interest, as would be the case if a 
clinician had made the choice for the person as a patient. 
Voluntariness
The concept of acting voluntarily is imprecise. Someone 
seems both voluntarily and involuntarily to hand over my 
wallet to the mugger with a knife. In UK law, the boundary 
is set by the equally imprecise notion of undue influence. In 
the case just described, the mugger is an undue influence on 
the victim’s action (31). In relation to clinical trials there are 
a number of factors that might be deemed undue influences, 
these include: inducements, particularly payments, a feeling 
of obligation to (or a fear of inferior treatment by) your 
clinicians who are also researchers, deference to clinicians 
deemed by participants to be socially superior, and 
desperation (21,32). 
The last has particular force in lung cancer trials and 
requires further explanation. People often make choices 
they would rather not: the mugging case is one example but 
another is a cancer patient who chooses to have surgery; 
in both cases it seems the best option of a bad lot. If the 
crime victim fails to hand over the wallet then physical 
harm may ensue. If the cancer patient fails to consent to 
the surgery then harm may ensue. But only in the first case 
does the person presenting the choice have control over 
that harm, he will directly cause the harm: that is the undue 
influence. A similar undue influence occurs where someone 
has control over good consequences, as when someone is 
offered a large amount of money to consent to a potentially 
harmful procedure. 
The problem with randomised trials is that some 
manipulation of choices and outcomes can appear to be 
involved. A decision to offer a treatment only through a 
randomised trial creates a situation where patients can only 
opt for a randomised chance of having that treatment. At 
this point the problem of equipoise can transform into one 
of coercion. Consider a patient diagnosed with a lung cancer 
who is thus seriously ill with a poor prognosis. He is told 
of a promising new treatment. The evidence base for this 
treatment is not strong enough to recommend it as a new 
standard and, therefore, a RCT has been set up. From the 
patient’s viewpoint, however, the existence of a treatment 
which is promising in a situation which is otherwise grim 
might be enough to recommend it: this person is desperate. 
By restricting his choice to a 50% chance of receiving the 
treatment he wants by opting for participation in a RCT 
have the researchers not exploited his vulnerability, put 
undue pressure on him to consent? A recent study of patients 
consenting to lung cancer surgery showed they had a high 
tolerance for perioperative mortality risk and that they 
tended to find it hard to imagine the risk eventuating (33). 
This supports the argument that equipoise of patients and 
clinicians could differ markedly. It also shows the difficulty 
of presenting information about risk in such a way that 
people can fully understand and weigh it up.
Faced with these problems it is worth asking the purpose 
of informed consent in relation to clinical trials. Consent 
has been central to research ethics at least since the period 
of the Nuremberg trials and the subsequent Nuremberg 
Code, whose opening statement is: “The voluntary 
consent of the human subject is absolutely essential” (34). 
However, whilst it is usually unacceptable to undertake 
clinical research without consent it does not follow that it 
is always acceptable provided there is consent. As well as 
consent procedures, Research Ethics Committees (RECs) 
also check inter alia the scientific validity of proposals 
and the balance of risks and benefits to participants. This 
suggests that RECs do not expect participants themselves 
necessarily to be able to do so. This offers some resolution 
of the information and understanding issues. We should 
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not and do not expect an ideal-type informed consent from 
participants. The role of informed consent is primarily 
to allow people to choose whether or not to take part in 
research based on their own beliefs and values. It does 
not override the responsibility of researchers and other 
professionals to ensure that any research offered to patients 
is ethically acceptable, that it does not, for example, expose 
them to undue risk even though they might not understand 
that risk (20). 
In order for informed consent to play this part of 
allowing people to choose, the capacity, information/
understanding and voluntariness criteria must still be met 
but to an extent that will vary between individuals. In this 
regard there are helpful guidelines on a minimum list of 
information which a person needs to be able to grasp if they 
are to be deemed to have capacity to consent. There are 
also non-standard ways in which consent can be obtained, 
for example, on a continuous or on a staged basis (35-37). If 
unable to do so, it would be better to talk in terms of assent 
rather than consent, or to use other measures for permission 
such as proxy consent. One of the items on any minimum 
list would certainly be an understanding that the person is 
taking part in a trial and that this is in some way different 
to standard treatment. Would this mean, therefore, that 
someone labouring under the therapeutic misconception 
has not given informed consent?
Kimmelman  note s  tha t  the  d i s cus s ion  o f  the 
misconception is located overwhelmingly in the United 
States (38,39). Perhaps one reason for this is the market-
based nature of health provision there in which the 
relationship between patient and clinician is an entirely 
private one, like that of solicitor and client. This differs 
from socialised health models in which the relationship is 
more like a club which provides services for its members. 
In the private model, a clinician whose aim is to improve 
his service to other clients rather than overwhelmingly to 
provide a service to the one in front of her is operating 
outside the boundaries of their agreement. A clinician 
cannot be both a private provider to a private client and 
a researcher at the same time. [The situation is different 
with clients unable to pay and who are then only able to 
receive treatment via consent to a study, see the fictional 
treatment of this in Shriver (40)]. With informed consent, 
this problem is overcome, provided that consent includes 
an understanding on the part of the client that the clinician 
is no longer acting as his private physician. In the socialised 
(club) model, for the clinician to act as researcher still 
requires consent, but there is no necessary conflict between 
the clinician’s role as the patient’s physician and as a 
researcher. 
It follows that under the socialised model, the participant 
who believes the physician is acting in his best interest 
when she treats him as part of a research protocol is not 
labouring under a therapeutic misconception because it 
is not a misconception. Snowdon et al. put this point well 
by invoking the idea of a an injurious misconception (41). 
It is well established that patients who take part in clinical 
trials generally do better than those who do not and that 
this is so whether in a control or treatment arm (42,43). 
Hence the injurious misconception exists in someone 
who avoids taking part in such trials on the basis of “an 
overstated sense of distinctions between care and research 
and a corresponding over-stated sense of risk and threat” 
(P199). Our suggestion, therefore, is that researchers and 
participants should not be overly exercised by the so-called 
therapeutic misconception. 
By contrast, the problem of undue influence and 
desperate volunteers is of import. Before asking how 
it might be tackled it is worth asking first whether it is 
ethically wrong to recruit participants to a randomised 
trial who have a strong preference to one arm. In other 
words, does limiting access to the preferred treatment in 
a randomised trial only constitute an undue influence on 
a patient’s consent to that trial? In an earlier article one 
of the present authors argued that it is not (32). In legal 
terms patients can refuse treatments and participation in 
research but they cannot demand it. No injustice is done in 
restricting a patient’s choice of a treatment to within a RCT 
only, this is, of course, provided the decision is equitable, 
without, for example, some patients being offered the 
treatment outside the trial whilst others not. In that sense, 
therefore, the restriction is not an ‘undue’ influence on the 
decision. 
However, avoiding injustice is not the whole story. The 
disappointment of desperate volunteers randomised to what 
is, from their perspective, the wrong arm is often palpable 
and has been recorded in some empirical research (41,44). 
Where possible it should be avoided and alleviated. Many 
of the suggestions already made could help here. PPI at 
trial inception should identify whether there is likely to be 
a widespread problem of lack of equipoise in participants. 
Where this is so, alternative trial designs such as patient 
preference types might be used. It might be possible to offer 
the treatments outside of the study without compromising 
the research, particularly where patient preferences are 
uncommon. Whilst there is no automatic right for a patient 
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to demand a novel treatment, it should be accommodated 
where possible.
Trial conduct
Once participants have been recruited to studies, some 
of the ethical issues faced in trial conduct will be fairly 
standard and dealt with using standard procedures, for 
example, those to do with privacy and confidentiality. Two 
issues might arise more sharply in lung cancer studies. 
These are related but are to do with, first, the welfare of 
patients and, second, the role of the Data Safety Monitoring 
Board (DSMB) or Data Monitoring Committee. 
The welfare of patients during trials is in part a product 
of the onerous nature of treatment, be it chemotherapy, 
radiotherapy, surgery or a combination. If given as treatment, 
a patient and clinician can reach agreement that one 
treatment mode needs adjustment or abandoning, perhaps 
to be replaced with another. This, of course, should also 
be the case for patients enrolled as research participants. 
The difficulty is that such changes to treatment may not be 
compatible with continuation in the trial. Both the clinician 
and the patient might feel some pressure to remain within the 
study. This pressure could be exacerbated where recruitment 
to the study is difficult. There are ways to reduce the risk of 
reluctant continuation: (I) provision of contact information 
of an advocate who can be easily contacted for decision 
making support; (II) care staff outside the trial able to suggest 
withdrawal; (III) design of study such that it facilitates early 
withdrawal but the possibility of using data collected up 
to that point; and (IV) the importance of feasibility studies 
preceding full clinical trials; for example, the MARS2 
feasibility study is focused strongly upon recruitment (45). 
In Lung Cancer studies a DSMB is almost always 
required. This adds a safeguard to participants where, for 
example, a new treatment turns out to be unexpectedly 
harmful or beneficial. Judging this is difficult, however. 
Stegart et al. (46) show that most trials that are stopped on 
the basis of either early benefit or futility have not followed 
stopping rules. Part of the problem here relates to the 
philosophy of statistics: a frequentist approach might tend 
to the later termination of a trial than a Bayesian one. But 
perhaps more significant is the role of value judgement 
relating to the weight to be given to some benefits and 
harms. This problem is in some ways a variation on the 
equipoise one and is particularly acute in lung cancer trials 
precisely because of the import of the trials’ potential 
benefits and harms. Just as patients with lung cancer may 
be less risk-averse than clinicians, so they might judge 
differently the need to stop a trial, for example, they might 
be more inclined to continue a trial despite a higher than 
expected mortality rate or to discontinue it where early 
signs of benefit are demonstrated. The use of PPI here may 
again help in making decisions about termination, as might 
the consideration of adopting Bayesian stopping rules (47). 
Trial dissemination
Failure to report trial results is unethical and the problem 
is widely acknowledged, particularly with regard to non-
publication of negative results (48,49). There are also 
measures in place to tackle them, such as through research 
registries. There seem to be no particular reasons to think 
these problems especially acute in lung cancer studies and 
so no more will be said here. 
Throughout this discussion reference has been made to 
PPI and its usefulness in tackling some of the ethical issues 
relating to lung cancer studies. Clearly that involvement of 
patients and public should continue into the dissemination 
stage, in publications and presentations for example. Brett’s 
review of PPI in health and social care research gives a 
number of examples but notes that examples of dissemination 
are unusual, found in only six of 200 papers (50). The six 
examples in a brief report from the National Cancer 
Research Institute similarly focus primarily on PPI as an 
aid to the setting up and running of studies rather than the 
dissemination and implementation of results (51). In the 
UK the work of the organisation involve has been central to 
developing PPI in cancer research (52).
Conclusions
As stated earlier, lung cancer trials do not give rise to 
unique ethical issues. However, features of such trials do 
tend to create some problems in acute forms. These features 
include the serious nature of the illness, the complexity of 
the trials and treatments, and the major harms associated 
with the treatments (such as chemotherapy and surgery). 
The problems these create relate to equipoise, consent and 
safety. Finally, developments in trial design and process such 
as PPI offer means for the researcher to alleviate but not to 
obviate these problems.
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